A 70-Year-Old Man with Early Relapsed/Refractory Multiple Myeloma
The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
Video content above is prompted by the following:
- Please share your initial impressions of the patient case.
- A decision to switch therapy was made. What regimen are you most likely to recommend for this patient?
- How do you set a patient up for the best success in early-stage R/R MM?
Recent Videos
Related Content
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025Article
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
